Pembrolizumab-associated tumor development in a patient with Sézary syndrome

Stephen J Malachowski; Leigh A Hatch; Lubomir Sokol; Jane Messina; Lucia Seminario-Vidal

doi:10.1016/j.jdcr.2019.11.005

Pembrolizumab-associated tumor development in a patient with Sézary syndrome

JAAD Case Rep. 2019 Dec 24;6(1):16-18. doi: 10.1016/j.jdcr.2019.11.005. eCollection 2020 Jan.

Authors

Stephen J Malachowski¹, Leigh A Hatch¹, Lubomir Sokol², Jane Messina^{3

4}, Lucia Seminario-Vidal^{1

4}

Affiliations

¹ Department of Dermatology, Morsani College of Medicine, University of South Florida, Tampa, Florida.
² Department of Malignant Hematology, Moffitt Center and Research Institute, Tampa, Florida.
³ Department of Anatomic Pathology, Moffitt Center and Research Institute, Tampa, Florida.
⁴ Department of Cutaneous Oncology, Moffitt Center and Research Institute, Tampa, Florida.

No abstract available

Keywords: BSA, body surface area; CTCL, cutaneous T-cell lymphoma; ECP, extracorporeal photopheresis; PD-1, programmed cell death-1; SS, Sézary syndrome; Sézary syndrome; cutaneous T-cell lymphoma; immunotherapy; pembrolizumab.

Publication types

Case Reports